[go: up one dir, main page]

AU2001267824A1 - Remedies for cancer - Google Patents

Remedies for cancer

Info

Publication number
AU2001267824A1
AU2001267824A1 AU2001267824A AU6782401A AU2001267824A1 AU 2001267824 A1 AU2001267824 A1 AU 2001267824A1 AU 2001267824 A AU2001267824 A AU 2001267824A AU 6782401 A AU6782401 A AU 6782401A AU 2001267824 A1 AU2001267824 A1 AU 2001267824A1
Authority
AU
Australia
Prior art keywords
cancer
remedies
useful
preventing
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001267824A
Inventor
Kohji Hanasaki
Minoru Ikeda
Takashi Ono
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of AU2001267824A1 publication Critical patent/AU2001267824A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

It is provided that type-X sPLA2 inhibitors are useful in preventing or treating cancer.
AU2001267824A 2000-06-29 2001-06-27 Remedies for cancer Abandoned AU2001267824A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-195434 2000-06-29
JP2000195434 2000-06-29
PCT/JP2001/005480 WO2002000255A1 (en) 2000-06-29 2001-06-27 Remedies for cancer

Publications (1)

Publication Number Publication Date
AU2001267824A1 true AU2001267824A1 (en) 2002-01-08

Family

ID=18694096

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001267824A Abandoned AU2001267824A1 (en) 2000-06-29 2001-06-27 Remedies for cancer

Country Status (8)

Country Link
US (1) US20040077651A1 (en)
EP (1) EP1300159B1 (en)
AT (1) ATE375171T1 (en)
AU (1) AU2001267824A1 (en)
DE (1) DE60130891T2 (en)
ES (1) ES2294003T3 (en)
TW (1) TW583000B (en)
WO (1) WO2002000255A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPS282602A0 (en) * 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
PT1852433E (en) 2004-10-29 2012-02-08 Zeria Pharm Co Ltd Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof
WO2008039023A1 (en) * 2006-09-29 2008-04-03 Green Cross Corporation Heteroaryl-pyrazole derivatives as cannabinoid cb1 receptor antagonists
CN102239182B (en) 2008-10-06 2014-07-09 米纳瓦生物技术公司 Antibody to MUC1*
MX2011011517A (en) 2009-04-29 2012-06-19 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same.
US9492460B2 (en) * 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
US5478857A (en) * 1993-12-23 1995-12-26 Eli Lilly And Company Use of PLA2 inhibitors as treatment for alzheimer's disease
RU2128169C1 (en) * 1994-04-01 1999-03-27 Эли Лилли Энд Компани 1h-indole-3-glyoxylamides inhibiting -mediated fatty acids releasing, a pharmaceutical composition
US5641800A (en) * 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
US5935860A (en) * 1995-03-07 1999-08-10 The George Washington University Use of uteroglobin expression as a molecular marker for prostatic intraepithelial neoplasia
WO1999024033A1 (en) * 1997-11-12 1999-05-20 Shionogi & Co., Ltd. Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds
EP1043991A4 (en) * 1997-11-14 2005-02-02 Lilly Co Eli Treatment for alzheimer's disease
JP3256513B2 (en) * 1998-02-11 2002-02-12 ファイザー製薬株式会社 Benzimidazole cyclooxygenase-2 inhibitor
US6028116A (en) * 1998-04-03 2000-02-22 Cell Pathways, Inc. Substituted condensation products of 1H-indenyl-hydroxyalkanes with aldehydes for neoplasia
DZ2769A1 (en) * 1998-04-17 2003-12-01 Lilly Co Eli Substituted tricyclics.
WO2000028997A1 (en) * 1998-11-12 2000-05-25 Analytica Ltd Phospholipase inhibitors for the treatment of cancer
AU7559600A (en) * 1999-10-15 2001-04-23 Shionogi & Co., Ltd. V type and/or x type spla2 inhibitors

Also Published As

Publication number Publication date
EP1300159A4 (en) 2005-08-24
TW583000B (en) 2004-04-11
ATE375171T1 (en) 2007-10-15
EP1300159A1 (en) 2003-04-09
DE60130891T2 (en) 2008-07-17
EP1300159B1 (en) 2007-10-10
US20040077651A1 (en) 2004-04-22
DE60130891D1 (en) 2007-11-22
WO2002000255A1 (en) 2002-01-03
ES2294003T3 (en) 2008-04-01

Similar Documents

Publication Publication Date Title
AU2002219472A1 (en) Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
AU2001227966A1 (en) Methods for treating tumors
AU2001252605A1 (en) Laser treatment apparatus
EP1210915A3 (en) Laser treatment apparatus
ZA200205887B (en) Liver tissue source.
AU2001239725A1 (en) Antibacterial agents
AU2003230750A1 (en) Compositions and methods for treating cancer
AU2002340139A1 (en) Inhibitors of the egf receptor for the treatment of thyroid cancer
AU2002248269A1 (en) Use of p38 inhibitors for the treatment of inflammation-enhanced cough
AU2001249626A1 (en) Cathepsin inhibitors in cancer treatment
AU2003225535A1 (en) Methods and compositions for treating cancer
AU2001260880A1 (en) Pharmaceutical compounds for treating copd
AU2002225930A1 (en) Methods for treating phosphatide-containing mixtures
AU7331300A (en) Method for treating or preventing chronic prostatitis or chronic pelvic pain syndrome
AU2001266838A1 (en) Inhibitors of matriptase for the treatment of cancer
MXPA03008582A (en) Agents and methods for treatment of cancer.
AU1359801A (en) Methods and compositions for treating reward deficiency syndrome
AU1028001A (en) Secretin fragments for treating autism
AU2002308642A1 (en) Methods for treating cancer
AU2001267824A1 (en) Remedies for cancer
AU2001232060A1 (en) Use of cyp1b1 inhibitors for treating cancer
EP1087479B8 (en) Stabilized laser source
IL139144A0 (en) Mycobacterial inhibitors
AU2002337713A1 (en) Pharmaceutical compositions and methods for treating cancer
AU2001243297A1 (en) Method for treating or preventing depression